All News #Library
Others
Prolynx Secures $70M Series A, Appoints Chris Boulton CEO
11 Dec 2025 //
GLOBENEWSWIRE
ProLynx Reports Preclinical Results Of Monthly Semaglutide
21 Aug 2024 //
GLOBENEWSWIRE
ProLynx announces initiation of Ph II trial of its DNA-damaging agent PLX038
07 Oct 2022 //
GLOBENEWSWIRE
ProLynx appoints Richard King as CEO and Chris Ehrlich as Board Director
20 Sep 2022 //
FIRSTWORLDPHARMA
ProLynx appoints Richard King as Chief Executive Officer and Chris Ehrlich
20 Sep 2022 //
GLOBENEWSWIRE
ProLynx announces SBIR grant award to develop long-acting parathyroid hormone
07 Jul 2020 //
GLOBENEWSWIRE

Market Place
Sourcing Support